Released Oct 26, 2026, before the open
10-Q filed Oct 26, 2026, 26 days after period end · 0001628280-26-067276
What the release said
Acumen Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Highlights
Acumen Pharmaceuticals reported cash, cash equivalents and marketable securities of $78.6 million as of September 30, 2026, compared with $110.2 million as of June 30, 2026.¶2
Research and development expenses were $21.1 million for the quarter ended September 30, 2026, compared with $22.0 million a year earlier, and general and administrative expenses were $4.7 million, compared with $4.5 million.¶3¶4
Loss from operations was $25.8 million for the quarter ended September 30, 2026, compared with $26.5 million, and net loss was $25.4 million, compared with $26.5 million.¶5¶6
- Cash, cash equivalents and marketable securities
- $78.6 million As of Sept. 30, 2026¶2
- Cash, cash equivalents and marketable securities
- $110.2 million As of June 30, 2026¶2
- Research and development expenses
- $21.1 million Quarter ended Sept. 30, 2026, compared to $22.0 million for the quarter ended Sept. 30, 2025¶3
- General and administrative expenses
- $4.7 million Quarter ended Sept. 30, 2026, compared to $4.5 million for the quarter ended Sept. 30, 2025¶4
- Loss from operations
- $25.8 million Quarter ended Sept. 30, 2026, compared to $26.5 million for the quarter ended Sept. 30, 2025¶5
- Net loss
- $25.4 million Quarter ended Sept. 30, 2026, compared to $26.5 million for the quarter ended Sept. 30, 2025¶6
Same quarter
| Metric | Q3 2026 | Q3 2025 | Q3 2024 | Q3 2023 |
|---|---|---|---|---|
| Net Income | -$25.37M | -$26.45M | -$29.77M | -$12.96M |
| EPS Diluted | -$0.35 | -$0.44 | -$0.50 | -$0.24 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Acumen Pharmaceuticals, Inc. · CIK 1576885 · Engraved from SEC EDGAR